To read the full story, subscribe or sign in.

Adalta gears up for phase II IPF trials for its i-body derived from shark antibodies

Aug. 15, 2023

Adalta Ltd. is gearing up to begin phase II trials of its lead i-body candidate, AD-214, in idiopathic pulmonary fibrosis (IPF), but it is hoping to find a pharma partner to fund the trials.

BioWorld BioWorld Asia Clinical Asia-Pacific Australia

Today's news in brief

BioWorld

BioWorld briefs for Sept. 28, 2023.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for September 28, 2023.

Dato data lack means upside for Gilead; Padcev 'must-win' does win

BioWorld

Upbeat phase III findings outweighed less encouraging late-stage trial news, as big pharma provided a mixed bag of cancer findings – with one data batch to form...

Illustration of Alzheimer’s in the brain.

Study identifies cause of death for Alzheimer’s neurons

BioWorld

By creating a new mouse model of Alzheimer’s disease that better recapitulated how the disease plays out in humans, investigators at KU Leuven have gained new...

Apple scores win over Masimo for patents for physiological detectors, but ITC decision awaits

BioWorld MedTech

Apple Inc., of Cupertino, Calif., has prevailed over Masimo Corp., in a ruling at the U.S. Court of Appeals for the Federal Circuit, an outcome that invalidated...

Upgrade your daily dose of biopharma and medtech news

Adalta gears up for phase II IPF trials for its i-body derived from shark antibodies